The NYT reported today that the German pharmaceutical company Bayer A.G. concealed a study from the F.D.A. that showed a drug used in heart surgery might increase the risks of strokes and death. Of course, economic theory predicts that government granted patent monopolies will create incentives for exactly this sort of behavior.
Economists should be focusing a large portion of their research to developing more efficient alternatives for financing pharmaceutical research. Unfortunately, they spend much more of their time calculating the gains from eliminating 5 percent tariffs on pants. As a result, tens of millions of people cannot afford drugs that would be sold at very low prices in a competitive (i.e. patent free) market, and drug regulators get lies about the safety of the drugs they evaluate.
If you enjoyed this article, please consider making a tax-deductible donation today. For over 30 years, The American Prospect has delivered independent reporting that exposes corporate power, investigates political corruption, and analyzes threats to our democracy. Unlike many media outlets, we’re not owned by billionaires or corporations—we’re powered by readers like you.
Today’s independent journalism faces unprecedented challenges. Your support makes our reporting possible and keeps our work free and accessible to all. Whether it’s $5 or $50, every contribution helps sustain our nonprofit newsroom.
Join our community of supporters and make a donation today to help keep independent journalism thriving.
Copyright 2025 | The American Prospect, Inc. | All Rights Reserved